Stabilized compositions of volatile alkylating agents and methods of using thereof
A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.
1. A topical composition comprising: (a) bis(2-chloroethyl)methylamine or a pharmaceutically acceptable salt thereof; and (b) a first and a second pharmaceutically acceptable excipient, wherein
the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.001% to about 2.0% by weight of the composition; and wherein
the first pharmaceutically acceptable excipient is a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 1-6 carbon atoms; and wherein
the second pharmaceutically acceptable excipient is butylated hydroxytoluene, edetate disodium, or benzyl alcohol.
2. The composition of claim 1 , wherein the bis(2-chloroethyl)methylamine is in the form of an acid-addition or base-addition salt.
3. The composition of claim 2 , comprising the acid-addition salt, wherein the acid-addition salt is an HCl, HBr, HI, H 2 SO 4 , or HNO 3 salt.
4. The composition of claim 3 , wherein the acid-addition salt is an HCl salt.
5. The composition of claim 1 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.01% to about 0.04% by weight of the composition.
6. The composition of claim 1 , wherein the second pharmaceutically acceptable excipient is butylated hydroxytoluene.
7. The composition of claim 1 , wherein the second pharmaceutically acceptable excipient is edetate disodium.
8. The composition of claim 7 , further comprising butylated hydroxytoluene.
9. The composition of claim 1 , wherein the first pharmaceutically acceptable excipient is a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 2 carbon atoms (ethoxy diglycol reagent).